Top

Published in:

01-07-2015 | Original Article - Genes and Disease

The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients

Authors: Tomas Soukup, Martin Dosedel, Petr Pavek, Jana Nekvindova, Ivan Barvik, Iva Bubancova, Petr Bradna, Ales Antonin Kubena, Alejandro Fernández Carazo, Tomas Veleta, Jiri Vlcek

Published in: Rheumatology International | Issue 7/2015

Abstract

Some single-nucleotide polymorphisms (SNPs) might be predictive of methotrexate (MTX) therapeutic outcome in rheumatoid arthritis (RA). The aim of this study was to determine whether SNPs in the methylenetetrahydrofolate reductase (MTHFR) gene are predictive of MTX response. Comparison was made using EULAR response criteria and according to the change of DAS28 (∆DAS28) after a 6-month MTX treatment in RA patient cohort. The two SNPs C677T (rs1801133) and A1298C (rs1801131) have been genotyped. A total of 120 patients were enrolled in the study, and all of them fulfilled the American College of Rheumatology 1987 RA criteria and are currently or previously taking MTX oral treatment, either as a monotherapy (n = 65) or in a combination with other disease-modifying antirheumatic drugs (n = 55). Genotyping was performed using qPCR allelic discrimination. We did not found any association of C677T and A1298C genotypes with MTX treatment inefficacy in dominant model (OR 1.23, 95 % CI 0.57–2.65, P = 0.697; and OR 0.98, 95 % CI 0.47–2.14, P = 1.0, respectively), or in recessive and codominant models. However, when ∆DAS28 after a 6-month therapy was used as a measure of treatment efficacy, the 677CT and 1298AC genotypes were found to be significantly associated with less favorable response to MTX (P = 0.025 and P = 0.043, respectively). In addition, even lower ∆DAS28 was determined for double-mutated 677CT–1298AC heterozygotes. It means that a synergistic effect of 677CT and 1298AC genotypes was observed. Nevertheless, the DAS28 baseline was lower here comparing to other genotypes. Unexpectedly, quite the opposite trend—i.e., better response to MTX—was found in genotypes 677CC–1298CC and 677TT–1298AA. It is an intriguing finding, because these double-mutated homozygotes are known for their low MTHFR-specific activity. Global significance was P = 0.013, η ² = 0.160—i.e., large-size effect. Thus, our data show greater ability of 677CC–1298CC and 677TT–1298AA genotypes to respond to MTX treatment.

Silman AJ, Hochberg MC (1993) Epidemiology of the rheumatic diseases. Oxford University Press, Oxford, pp 14–19

Gaujoux-Viala C, Nam J, Ramiro S, Landewe R, Buch MH, Smolen JS, Gossec L (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510–515. doi:10.1136/annrheumdis-2013-204588 CrossRefPubMedCentralPubMed

Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, Emery P, Gaujoux-Viala C, Gossec L, Nam J, Ramiro S, Winthrop K, de Wit M, Aletaha D, Betteridge N, Bijlsma JW, Boers M, Buttgereit F, Combe B, Cutolo M, Damjanov N, Hazes JM, Kouloumas M, Kvien TK, Mariette X, Pavelka K, van Riel PL, Rubbert-Roth A, Scholte-Voshaar M, Scott DL, Sokka-Isler T, Wong JB, van der Heijde D (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509. doi:10.1136/annrheumdis-2013-204573 CrossRefPubMedCentralPubMed

Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21(5 Suppl 31):S179–S185PubMed

Aletaha D, Funovits J, Smolen JS (2008) The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis Rheum 58(9):2622–2631. doi:10.1002/art.23733 CrossRefPubMed

Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, Santra S, Smolen JS (2013) Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 72(1):64–71. doi:10.1136/annrheumdis-2011-201247 CrossRefPubMedCentralPubMed

Breedveld P, Pluim D, Cipriani G, Wielinga P, van Tellingen O, Schinkel AH, Schellens JH (2005) The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 65(7):2577–2582. doi:10.1158/0008-5472.CAN-04-2416 CrossRefPubMed

St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-controlled study of patients receiving infliximab for the treatment of rheumatoid arthritis of early onset study G (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443. doi:10.1002/art.20568

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola EM, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M (2004) Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363(9410):675–681. doi:10.1016/S0140-6736(04)15640-7 CrossRefPubMed

10.

Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Covucci A, Helfrick R, Bathon J (2009) Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 68(12):1870–1877. doi:10.1136/ard.2008.101121 CrossRefPubMedCentralPubMed

11.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71(3):351–357. doi:10.1136/annrheumdis-2011-200170 CrossRefPubMedCentralPubMed

12.

Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, Bijkerk C, Speyer I, de Buck MP, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF (2014) A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study. Ann Rheum Dis 73(7):1356–1361. doi:10.1136/annrheumdis-2013-203243 CrossRefPubMed

13.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54(1):26–37. doi:10.1002/art.21519 CrossRefPubMed

14.

Salliot C, van der Heijde D (2009) Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 68(7):1100–1104. doi:10.1136/ard.2008.093690 CrossRefPubMedCentralPubMed

15.

Visser K, van der Heijde D (2009) Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 68(7):1094–1099. doi:10.1136/ard.2008.092668 CrossRefPubMedCentralPubMed

16.

Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ (2010) Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. Pharmacogenomics 11(2):163–175. doi:10.2217/pgs.09.139 CrossRefPubMed

17.

Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, Laasonen L, Julkunen H, Luukkainen R, Vuori K, Paimela L, Blafield H, Hakala M, Ilva K, Yli-Kerttula U, Puolakka K, Jarvinen P, Hakola M, Piirainen H, Ahonen J, Palvimaki I, Forsberg S, Koota K, Friman C (1999) Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164):1568–1573CrossRefPubMed

18.

Chan ES, Cronstein BN (2013) Mechanisms of action of methotrexate. Bull Hosp Jt Dis 71(Suppl 1):S5–S8

19.

Lee YH, Song GG (2010) Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin Drug Investig 30(2):101–108. doi:10.2165/11531070-000000000-00000 CrossRefPubMed

20.

Kooloos WM, Huizinga TW, Guchelaar HJ, Wessels JA (2010) Pharmacogenetics in treatment of rheumatoid arthritis. Curr Pharm Des 16(2):164–175CrossRefPubMed

21.

Gervasini G (2009) Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 10(6):547–566CrossRefPubMed

22.

Brinker RR, Ranganathan P (2010) Methotrexate pharmacogenetics in rheumatoid arthritis. Clin Exp Rheumatol 28(5 Suppl 61):S33–S39PubMed

23.

Owen SA, Lunt M, Bowes J, Hider SL, Bruce IN, Thomson W, Barton A (2013) MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. Pharmacogenomics J 13(2):137–147. doi:10.1038/tpj.2011.42 CrossRefPubMed

24.

Aletaha D, Smolen JS (2006) The definition and measurement of disease modification in inflammatory rheumatic diseases. Rheum Dis Clin N Am 32(1):9–44, vii. doi:10.1016/j.rdc.2005.09.005

25.

van Riel PL, van Gestel AM (2000) Clinical outcome measures in rheumatoid arthritis. Ann Rheum Dis 59(Suppl 1):i28–i31CrossRefPubMedCentralPubMed

26.

van Gestel AM, Prevoo ML, Van‘t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL (1996) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39(1):34–40CrossRefPubMed

27.

Wessels JA, van der Kooij SM, le Cessie S, Kievit W, Barerra P, Allaart CF, Huizinga TW, Guchelaar HJ (2007) A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 56(6):1765–1775. doi:10.1002/art.22640 CrossRefPubMed

28.

Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43(1):22–29. doi:10.1002/1529-0131(200001)43:1<22:AID-ANR4>3.0.CO;2-9 CrossRefPubMed

29.

Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, den Heijer M, Kluijtmans LA, van den Heuvel LP et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111–113. doi:10.1038/ng0595-111 CrossRefPubMed

30.

Chango A, Boisson F, Barbe F, Quilliot D, Droesch S, Pfister M, Fillon-Emery N, Lambert D, Fremont S, Rosenblatt DS, Nicolas JP (2000) The effect of 677C–>T and 1298A–>C mutations on plasma homocysteine and 5,10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutr 83(6):593–596CrossRefPubMed

31.

van der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, van den Heuvel LP, Blom HJ (1998) A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects? Am J Hum Genet 62(5):1044–1051. doi:10.1086/301825 CrossRefPubMedCentralPubMed

32.

Cronstein BN (2005) Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 57(2):163–172. doi:10.1124/pr.57.2.3 CrossRefPubMed

33.

Papadopoulos NG, Alamanos Y, Voulgari PV, Epagelis EK, Tsifetaki N, Drosos AA (2005) Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol 23(6):861–866PubMed

34.

Imboden JB, Hellmann DB, Stone JH (2006) Rheumatoid arthritis: the disease-diagnosis and clinical features. In: Imboden JB, Hellmann DB, Stone JH (eds) Current rheumatology diagnosis & treatment, vol 2. McGraw Hill Professional, New York, p 508

35.

Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26(2):201–204. doi:10.1007/s10067-006-0275-5 CrossRefPubMed

36.

Lima A, Monteiro J, Bernardes M, Sousa H, Azevedo R, Seabra V, Medeiros R (2014) Prediction of methotrexate clinical response in Portuguese rheumatoid arthritis patients: implication of MTHFR rs1801133 and ATIC rs4673993 polymorphisms. BioMed Res Int 2014:368681. doi:10.1155/2014/368681 PubMedCentralPubMed

37.

Yamada K, Chen Z, Rozen R, Matthews RG (2001) Effects of common polymorphisms on the properties of recombinant human methylenetetrahydrofolate reductase. Proc Natl Acad Sci USA 98(26):14853–14858. doi:10.1073/pnas.261469998 CrossRefPubMedCentralPubMed

38.

Peake JN, Copp AJ, Shawe J (2013) Knowledge and periconceptional use of folic acid for the prevention of neural tube defects in ethnic communities in the United Kingdom: systematic review and meta-analysis. Birth Defects Res A Clin Mol Teratol 97(7):444–451. doi:10.1002/bdra.23154 CrossRefPubMedCentralPubMed

39.

Liu N, Jiang J, Song YJ, Zhao SG, Tong ZG, Song HS, Wu H, Zhu JY, Gu YH, Sun Y, Hua W, Qi JP (2013) Impact of MTHFR polymorphisms on methylation of MGMT in glioma patients from Northeast China with different folate levels. Genet Mol Res: GMR 12(4):5160–5171. doi:10.4238/2013.October.29.10 CrossRefPubMed

40.

Szabo GV (2013) The role and importance of gene polymorphisms in the development of atherosclerosis. Interv Med Appl Sci 5(1):46–51. doi:10.1556/IMAS.5.2013.1.10 CrossRefPubMedCentralPubMed

41.

Karata S, Aydin Y, Ocer F, Buyru A, Balci H (2012) Hereditary thrombophilia, anti-beta2 glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 67(3):251–255. doi:10.1111/j.1600-0897.2011.01092.x CrossRefPubMed

42.

Tsai SJ, Hong CJ, Yeh HL, Liou YJ, Yang AC, Liu ME, Hwang JP (2011) Heterozygote advantage of the MTHFR C677T polymorphism on specific cognitive performance in elderly Chinese males without dementia. Dement Geriatr Cogn Disord 32(3):159–163. doi:10.1159/000333074 CrossRefPubMed

43.

Morgan MD, Al-Shaarawy N, Martin S, Robinson JI, Twigg S, Consortium Y, Magdy AA, Omar AS, Ghattas MH, Emery P, Barrett JH, Morgan AW (2014) MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. Pharmacogenomics 15(4):467–475. doi:10.2217/pgs.13.235 CrossRef

44.

Fisher MC, Cronstein BN (2009) Metaanalysis of methylenetetrahydrofolate reductase (MTHFR) polymorphisms affecting methotrexate toxicity. J Rheumatol 36(3):539–545. doi:10.3899/jrheum.080576 CrossRefPubMedCentralPubMed

45.

Song GG, Bae SC, Lee YH (2014) Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis. Clin Rheumatol. doi:10.1007/s10067-014-2645-8

46.

Spyridopoulou KP, Dimou NL, Hamodrakas SJ, Bagos PG (2012) Methylene tetrahydrofolate reductase gene polymorphisms and their association with methotrexate toxicity: a meta-analysis. Pharmacogenet Genomics 22(2):117–133. doi:10.1097/FPC.0b013e32834ded2a CrossRefPubMed

47.

Salazar J, Moya P, Altes A, Diaz-Torne C, Casademont J, Cerda-Gabaroi D, Corominas H, Baiget M (2014) Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients? Pharmacogenomics 15(8):1079–1090. doi:10.2217/pgs.14.67 CrossRefPubMed

48.

Aletaha D, Smolen JS (2002) Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. J Rheumatol 29(8):1631–1638PubMed

49.

Fekih-Mrissa N, Mrad M, Klai S, Mansour M, Nsiri B, Gritli N, Mrissa R (2013) Methylenetetrahydrofolate reductase (C677T and A1298C) polymorphisms, hyperhomocysteinemia, and ischemic stroke in Tunisian patients. J Stroke Cerebrovasc Dis: Off J Natl Stroke Assoc 22(4):465–469. doi:10.1016/j.jstrokecerebrovasdis.2013.03.011 CrossRef

50.

Choe JY, Lee H, Jung HY, Park SH, Bae SC, Kim SK (2012) Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int 32(6):1837–1842. doi:10.1007/s00296-011-1989-5 CrossRefPubMed

51.

Isotalo PA, Wells GA, Donnelly JG (2000) Neonatal and fetal methylenetetrahydrofolate reductase genetic polymorphisms: an examination of C677T and A1298C mutations. Am J Hum Genet 67(4):986–990. doi:10.1086/303082 CrossRefPubMedCentralPubMed

Title: The impact of C677T and A1298C MTHFR polymorphisms on methotrexate therapeutic response in East Bohemian region rheumatoid arthritis patients
Authors: Tomas Soukup
Martin Dosedel
Petr Pavek
Jana Nekvindova
Ivan Barvik
Iva Bubancova
Petr Bradna
Ales Antonin Kubena
Alejandro Fernández Carazo
Tomas Veleta
Jiri Vlcek
Publication date: 01-07-2015
Publisher: Springer Berlin Heidelberg
Published in: Rheumatology International / Issue 7/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-015-3219-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2015

Erratum to: Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis

Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis

Relationship between cigarette smoking and radiographic knee osteoarthritis in Chinese population: a cross-sectional study

Current cigarette use in rheumatoid arthritis patients: associated factors and a limited mediating role of depression

Ageing influence in the evolution of strength and muscle mass in women with fibromyalgia: the al-Ándalus project

The association between comorbidities and pain, physical function and quality of life following hip and knee arthroplasty

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials